Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:00 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Intravenous Versus Intramuscular Administration of Methylergonovine for Uterine Contraction in Cesarean Sections
NCT03303235 · Johns Hopkins University · EARLY_PHASE1 · withdrawn · last registry update 2020-08-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Collaborators left the institution.” | – | Registry record, Johns Hopkins University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2B within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-11-25Also stopped (terminated): RWTH Aachen University, Maintenance treatment + Intermittent treatment (NCT02435095)
- 2020-08-27Phase 3 first posted: Shanghai Mental Health Center, Clozapine (NCT04528095)
- 2019-09-06Results posted on the registry: University of California, San Francisco, Methergine (NCT02408965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision